OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104

13 October 2020

The patent covers novel dosing regimen of FR104 in Europe through 2036 for therapeutic applications in autoimmune diseases, inflammatory diseases, transplantation and graft-versus-host disease

Nantes, France, October 12, 2020, 6:00PM CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced the European Patent Office’s(EPO) issuance of a notice of allowance for its Phase-2 ready product FR104, a first-in-class selective CD28-antagonist. Specifically, this European patent will provide additional protection covering novel dosing regimen of FR104 for the prevention and treatment of T-lymphocyte-mediated autoimmune diseases, inflammatory diseases, transplantation and graft-versus-host disease (GVHD) until

Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, commented, “This new notice of allowance from the EPO broadens the global patent protection of FR104 and similar patent applications are pending in other countries. As a Phase 2-ready product with Phase 1 signals of clinical efficacy and strong safety profile, FR104 is a valuable asset with great potential for further development to meet patients’ needs in a number of autoimmune conditions, in transplantation and as prevention of graftversus-host disease following hematopoietic stem cell transplantation.”

CD28 blockade by FR104 tackles memory pathogenic T lymphocytes while favoring Treg suppressive function. This novel mechanism of controlling immune synapses potentially offers new therapeutic options in multiple inflammatory and autoimmune diseases, transplantation and GVHD where T cells are involved. The results from FR104’s Phase 1 clinical study have shown initial signals of efficacy, a good safety profile and the recommended dose for a Phase 2, further supporting the continued clinical development of this asset.